It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
An inverse association between cancer and Alzheimer’s disease (AD) has been demonstrated; however, the association between cancer and mild cognitive impairment (MCI), and the association between cancer and cognitive decline are yet to be clarified. The AIBL dataset was used to address these knowledge gaps. The crude and adjusted odds ratios for MCI/AD and cognitive decline were compared between participants with/without cancer (referred to as C+ and C− participants). A 37% reduction in odds for AD was observed in C+ participants compared to C− participants after adjusting for all confounders. The overall risk for MCI and AD in C+ participants was reduced by 27% and 31%, respectively. The odds of cognitive decline from MCI to AD was reduced by 59% in C+ participants after adjusting for all confounders. The risk of cognitive decline from MCI to AD was halved in C+ participants. The estimated mean change in Clinical Dementia Rating-Sum of boxes (CDR-SOB) score per year was 0.23 units/year higher in C− participants than in C+ participants. Overall, an inverse association between cancer and MCI/AD was observed in AIBL, which is in line with previous reports. Importantly, an inverse association between cancer and cognitive decline has also been identified.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The University of Melbourne, Florey Institute of Neuroscience and Mental Health, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
2 The University of Sydney, The University of Sydney School of Pharmacy, Faculty of Medicine and Health, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X)
3 The University of Melbourne, Florey Institute of Neuroscience and Mental Health, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Monash University, Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Parkville, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
4 The University of Melbourne, Florey Institute of Neuroscience and Mental Health, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Monash University, Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Parkville, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Tohoku University, Department of Organ Anatomy, Graduate School of Medicine, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943)